Insulin aspart
Brand names: NovoRapid, Fiasp
A rapid-acting insulin analogue used at mealtimes in diabetes, suitable for subcutaneous injection, insulin pumps, and intravenous use in acute care.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Structural modification of the insulin molecule speeds subcutaneous absorption, giving a faster onset and shorter duration than soluble human insulin and allowing dosing close to meals.
Prescribing in practice
- The most important safety point is the risk of hypoglycaemia, with insulin being a high-alert medicine; prescribe in units written in full, use insulin-specific devices, and dose around meals.
- Because of its rapid onset it is given just before or shortly after eating, and unexpected delays in eating increase hypoglycaemia risk.
- Different insulin brands and analogues are not interchangeable, so prescribe and dispense by brand.
Monitoring
Monitor blood glucose around meals and overnight, titrating mealtime doses to carbohydrate intake and glucose response.
Counselling the patient
- Inject just before eating and have fast-acting carbohydrate available in case of hypoglycaemia.
- Rotate injection sites to prevent lipohypertrophy and check sites regularly.
- Do not switch insulin brand or type without specialist advice.
Evidence & guidelines
Rapid-acting analogues such as insulin aspart are recommended in NICE diabetes guidance for mealtime control, and insulin is classified as a high-alert medicine.
Reference: NICE NG17/NG28; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016